Last 12 months
Inside the activity.
0 purchase rows · 10 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 5 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 2 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 08, 2017 Filed Mar 10, 2017 21:19 UTC |
STAAB THOMAS R IISenior Vice President and CFO
|
SaleCommon Stock | 3,250 | $8.65 | $28,112.50 |
DisclosureSEC source: 0001127602-17-011240 · form4.xml · nonDerivative · entry 3 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,313 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2016. Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 21:19 UTC |
STAAB THOMAS R IISenior Vice President and CFO
|
SaleCommon Stock | 3,250 | $8.20 | $26,650.00 |
DisclosureSEC source: 0001127602-17-011240 · form4.xml · nonDerivative · entry 2 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,563 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2016. Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 21:19 UTC |
STAAB THOMAS R IISenior Vice President and CFO
|
Exercise / conversionCommon Stock | 6,500 | $3.78 | $24,570.00 |
DisclosureSEC source: 0001127602-17-011240 · form4.xml · nonDerivative · entry 1 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,813 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2016. Read SEC document |
| March 06, 2017 Filed Mar 8, 2017 13:05 UTC |
STAAB THOMAS R IISenior Vice President and CFO
|
Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 3,250 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0001127602-17-010729 · form4.xml · derivative · entry 3 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,760 Underlying: Common Stock · 3,250 shares Expires 2021-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2017 Filed Mar 8, 2017 13:05 UTC |
STAAB THOMAS R IISenior Vice President and CFO
|
SaleCommon Stock | 3,250 | $7.90 | $25,675.00 |
DisclosureSEC source: 0001127602-17-010729 · form4.xml · nonDerivative · entry 2 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,313 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2016. Read SEC document |
| March 06, 2017 Filed Mar 8, 2017 13:05 UTC |
STAAB THOMAS R IISenior Vice President and CFO
|
Exercise / conversionCommon Stock | 3,250 | $3.78 | $12,285.00 |
DisclosureSEC source: 0001127602-17-010729 · form4.xml · nonDerivative · entry 1 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,563 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2016. Read SEC document |
| March 02, 2017 Filed Mar 2, 2017 20:07 UTC |
INGRAM ROBERT ALEXANDERDirector
|
GrantCommon Stock | 1,602 | $6.24 | $9,996.48 |
DisclosureSEC source: 0001127602-17-009570 · form4.xml · nonDerivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,823 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000. Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 20:05 UTC |
Hutson Nancy JDirector
|
GrantCommon Stock | 1,602 | $6.24 | $9,996.48 |
DisclosureSEC source: 0001127602-17-009568 · form4.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,266 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000. Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 20:03 UTC |
Cohen Fred EDirector
|
GrantCommon Stock | 1,602 | $6.24 | $9,996.48 |
DisclosureSEC source: 0001127602-17-009566 · form4.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,469 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 20:07 UTC |
Powell LynneSenior VP - CCO
|
GrantEmp. Stock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $5.51 | $0.00 |
DisclosureSEC source: 0001127602-17-009161 · form4.xml · derivative · entry 1 Powell Lynne · CIK 0001631667 · Senior VP - CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2027-02-27 F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 18:53 UTC |
Barnes Alane PVP, General Counsel & Corp Sec
|
GrantEmp. Stock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $5.51 | $0.00 |
DisclosureSEC source: 0001127602-17-009101 · form4.xml · derivative · entry 1 Barnes Alane P · CIK 0001584348 · VP, General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2027-02-27 F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 18:50 UTC |
Babu Yarlagadda SSenior VP - Drug Discovery
|
GrantEmp. Stock Option (Right to Buy) · Derivative | 175,000 | $0.00 Strike: $5.51 | $0.00 |
DisclosureSEC source: 0001127602-17-009099 · form4.xml · derivative · entry 1 Babu Yarlagadda S · CIK 0001452635 · Senior VP - Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2027-02-27 F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 18:48 UTC |
Sheridan William PSenior VP - CMO
|
GrantEmp. Stock Option (Right to Buy) · Derivative | 175,000 | $0.00 Strike: $5.51 | $0.00 |
DisclosureSEC source: 0001127602-17-009095 · form4.xml · derivative · entry 1 Sheridan William P · CIK 0001439174 · Senior VP - CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2027-02-27 F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 18:46 UTC |
STAAB THOMAS R IISenior Vice President and CFO
|
GrantEmp. Stock Option (Right to Buy) · Derivative | 175,000 | $0.00 Strike: $5.51 | $0.00 |
DisclosureSEC source: 0001127602-17-009091 · form4.xml · derivative · entry 1 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2027-02-27 F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 18:43 UTC |
Stonehouse Jon PDirector · President & CEO
|
GrantEmp. Stock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $5.51 | $0.00 |
DisclosureSEC source: 0001127602-17-009089 · form4.xml · derivative · entry 1 Stonehouse Jon P · CIK 0001385496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2027-02-27 F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| January 20, 2017 Filed Jan 24, 2017 14:28 UTC |
Barnes Alane PVP, General Counsel & Corp Sec
|
Tax withholdingCommon Stock | 2,599 | $5.95 | $15,464.05 |
DisclosureSEC source: 0001127602-17-002252 · form4.xml · nonDerivative · entry 1 Barnes Alane P · CIK 0001584348 · VP, General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,497 F1 · shares: Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's federal and state tax withholding obligations upon the vesting of restricted stock units granted in 2014. Read SEC document |
| January 20, 2017 Filed Jan 24, 2017 14:25 UTC |
Babu Yarlagadda SSenior VP - Drug Discovery
|
Tax withholdingCommon Stock | 5,083 | $5.95 | $30,243.85 |
DisclosureSEC source: 0001127602-17-002250 · form4.xml · nonDerivative · entry 1 Babu Yarlagadda S · CIK 0001452635 · Senior VP - Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,706 F1 · shares: Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's federal and state tax withholding obligations upon the vesting of restricted stock units granted in 2014. Read SEC document |
| January 20, 2017 Filed Jan 24, 2017 14:22 UTC |
Sheridan William PSenior VP - CMO
|
Tax withholdingCommon Stock | 5,761 | $5.95 | $34,277.95 |
DisclosureSEC source: 0001127602-17-002248 · form4.xml · nonDerivative · entry 1 Sheridan William P · CIK 0001439174 · Senior VP - CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,916 F1 · shares: Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's federal and state tax withholding obligations upon the vesting of restricted stock units granted in 2014. Read SEC document |
| January 20, 2017 Filed Jan 24, 2017 14:20 UTC |
STAAB THOMAS R IISenior Vice President and CFO
|
Tax withholdingCommon Stock | 5,198 | $5.95 | $30,928.10 |
DisclosureSEC source: 0001127602-17-002246 · form4.xml · nonDerivative · entry 1 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,313 F1 · shares: Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's federal and state tax withholding obligations upon the vesting of restricted stock units granted in 2014. Read SEC document |
| January 20, 2017 Filed Jan 24, 2017 14:17 UTC |
Stonehouse Jon PDirector · President & CEO
|
Tax withholdingCommon Stock | 10,572 | $5.95 | $62,903.40 |
DisclosureSEC source: 0001127602-17-002244 · form4.xml · nonDerivative · entry 1 Stonehouse Jon P · CIK 0001385496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 645,418 F1 · shares: Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's federal and state tax withholding obligations upon the vesting of restricted stock units granted in 2014. Read SEC document |
| January 01, 2017 Filed Jan 3, 2017 19:03 UTC |
STAAB THOMAS R IISenior Vice President and CFO
|
Tax withholdingCommon Stock | 1,676 | $6.33 | $10,609.08 |
DisclosureSEC source: 0001127602-17-000063 · form4.xml · nonDerivative · entry 1 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,511 F1 · shares: Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2013 and 2015. Read SEC document |
| January 01, 2017 Filed Jan 3, 2017 19:13 UTC |
Barnes Alane PVP, General Counsel & Corp Sec
|
Tax withholdingCommon Stock | 1,281 | $6.33 | $8,108.73 |
DisclosureSEC source: 0001127602-17-000087 · form4.xml · nonDerivative · entry 1 Barnes Alane P · CIK 0001584348 · VP, General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,096 F1 · shares: Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2013 and 2015. Read SEC document |
| January 01, 2017 Filed Jan 3, 2017 19:09 UTC |
Babu Yarlagadda SSenior VP - Drug Discovery
|
Tax withholdingCommon Stock | 1,639 | $6.33 | $10,374.87 |
DisclosureSEC source: 0001127602-17-000077 · form4.xml · nonDerivative · entry 1 Babu Yarlagadda S · CIK 0001452635 · Senior VP - Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,789 F1 · shares: Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2013 and 2015. Read SEC document |
| January 01, 2017 Filed Jan 3, 2017 19:06 UTC |
Sheridan William PSenior VP - CMO
|
Tax withholdingCommon Stock | 2,081 | $6.33 | $13,172.73 |
DisclosureSEC source: 0001127602-17-000069 · form4.xml · nonDerivative · entry 1 Sheridan William P · CIK 0001439174 · Senior VP - CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,677 F1 · shares: Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2013 and 2015. Read SEC document |
| January 01, 2017 Filed Jan 3, 2017 18:59 UTC |
Stonehouse Jon PDirector · President & CEO
|
Tax withholdingCommon Stock | 8,595 | $6.33 | $54,406.35 |
DisclosureSEC source: 0001127602-17-000060 · form4.xml · nonDerivative · entry 1 Stonehouse Jon P · CIK 0001385496 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 655,990 F1 · shares: Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2013 and 2015. Read SEC document |
| December 19, 2016 Filed Dec 21, 2016 15:42 UTC |
STAAB THOMAS R IISenior Vice President and CFO
|
Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 3,250 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0001127602-16-070634 · form4.xml · derivative · entry 3 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,010 Underlying: Common Stock · 3,250 shares Expires 2021-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 19, 2016 Filed Dec 21, 2016 15:42 UTC |
STAAB THOMAS R IISenior Vice President and CFO
|
SaleCommon Stock | 3,250 | $7.45 | $24,212.50 |
DisclosureSEC source: 0001127602-16-070634 · form4.xml · nonDerivative · entry 2 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,187 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2016. Read SEC document |
| December 19, 2016 Filed Dec 21, 2016 15:42 UTC |
STAAB THOMAS R IISenior Vice President and CFO
|
Exercise / conversionCommon Stock | 3,250 | $3.78 | $12,285.00 |
DisclosureSEC source: 0001127602-16-070634 · form4.xml · nonDerivative · entry 1 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,437 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2016. Read SEC document |
| December 01, 2016 Filed Dec 2, 2016 19:09 UTC |
INGRAM ROBERT ALEXANDERDirector
|
GrantCommon Stock | 1,788 | $5.59 | $9,994.92 |
DisclosureSEC source: 0001127602-16-068910 · form4.xml · nonDerivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,221 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000. Read SEC document |
| December 01, 2016 Filed Dec 2, 2016 19:06 UTC |
Hutson Nancy JDirector
|
GrantCommon Stock | 1,788 | $5.59 | $9,994.92 |
DisclosureSEC source: 0001127602-16-068908 · form4.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,664 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000. Read SEC document |
| December 01, 2016 Filed Dec 2, 2016 19:03 UTC |
Cohen Fred EDirector
|
GrantCommon Stock | 1,788 | $5.59 | $9,994.92 |
DisclosureSEC source: 0001127602-16-068905 · form4.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,867 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000. Read SEC document |
| September 14, 2016 Filed Sep 16, 2016 14:54 UTC |
Barnes Alane PVP, General Counsel & Corp Sec
|
SaleCommon Stock | 8,357 | $4.27 | $35,684.39 |
DisclosureSEC source: 0001127602-16-062585 · form4.xml · nonDerivative · entry 1 Barnes Alane P · CIK 0001584348 · VP, General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,377 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 17, 2016. F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $4.22 to $4.31. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| September 01, 2016 Filed Sep 6, 2016 19:24 UTC |
Cohen Fred EDirector
|
GrantCommon Stock | 2,433 | $4.11 | $9,999.63 |
DisclosureSEC source: 0001127602-16-061901 · form4.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,079 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000. Read SEC document |
| September 01, 2016 Filed Sep 6, 2016 19:27 UTC |
INGRAM ROBERT ALEXANDERDirector
|
GrantCommon Stock | 2,433 | $4.11 | $9,999.63 |
DisclosureSEC source: 0001127602-16-061906 · form4.xml · nonDerivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,433 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000. Read SEC document |
| September 01, 2016 Filed Sep 6, 2016 19:25 UTC |
Hutson Nancy JDirector
|
GrantCommon Stock | 2,433 | $4.11 | $9,999.63 |
DisclosureSEC source: 0001127602-16-061903 · form4.xml · nonDerivative · entry 1 Hutson Nancy J · CIK 0001379222 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,876 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.